Intellectus Partners LLC Sells 35,850 Shares of Intellia Therapeutics, Inc. $NTLA

Intellectus Partners LLC lowered its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 41.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 51,125 shares of the company’s stock after selling 35,850 shares during the quarter. Intellectus Partners LLC’s holdings in Intellia Therapeutics were worth $460,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the stock. Oppenheimer & Co. Inc. raised its stake in shares of Intellia Therapeutics by 0.8% in the fourth quarter. Oppenheimer & Co. Inc. now owns 105,165 shares of the company’s stock worth $945,000 after buying an additional 808 shares during the period. Comerica Bank raised its stake in shares of Intellia Therapeutics by 45.8% in the fourth quarter. Comerica Bank now owns 2,869 shares of the company’s stock worth $26,000 after buying an additional 901 shares during the period. Federated Hermes Inc. raised its stake in shares of Intellia Therapeutics by 39.7% in the third quarter. Federated Hermes Inc. now owns 3,263 shares of the company’s stock worth $56,000 after buying an additional 927 shares during the period. Interchange Capital Partners LLC raised its stake in shares of Intellia Therapeutics by 9.7% in the third quarter. Interchange Capital Partners LLC now owns 11,695 shares of the company’s stock worth $202,000 after buying an additional 1,030 shares during the period. Finally, Benjamin Edwards Inc. raised its stake in shares of Intellia Therapeutics by 1.8% in the second quarter. Benjamin Edwards Inc. now owns 63,034 shares of the company’s stock worth $591,000 after buying an additional 1,126 shares during the period. Institutional investors own 88.77% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on NTLA shares. The Goldman Sachs Group raised their price objective on Intellia Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a research note on Tuesday, April 28th. Bank of America reaffirmed a “neutral” rating on shares of Intellia Therapeutics in a research note on Monday, March 2nd. Morgan Stanley raised their price objective on Intellia Therapeutics from $11.00 to $15.00 and gave the stock an “equal weight” rating in a research note on Monday, April 27th. Wedbush reissued a “neutral” rating and set a $12.00 target price on shares of Intellia Therapeutics in a research note on Tuesday, May 12th. Finally, Wall Street Zen downgraded Intellia Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $20.25.

Intellia Therapeutics Trading Up 13.3%

Shares of NTLA opened at $14.75 on Friday. The business’s 50 day moving average is $13.60 and its 200 day moving average is $12.13. The company has a market capitalization of $2.06 billion, a PE ratio of -4.17 and a beta of 1.92. Intellia Therapeutics, Inc. has a 12-month low of $7.31 and a 12-month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.11. The company had revenue of $15.05 million for the quarter, compared to the consensus estimate of $13.81 million. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.During the same quarter last year, the company earned ($1.10) EPS. Equities research analysts predict that Intellia Therapeutics, Inc. will post -3.29 earnings per share for the current year.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.